Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases. Its lead asset Descartes-08 is in Phase 2b development for generalized myasthenia gravis.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
CAR T-cell therapy market advances with AI-driven manufacturing improvements and over 250 companies developing 500+ drug candidates, including breakthrough solid tumor treatments and GPC3-targeted therapies for hepatocellular carcinoma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07391605 |
Descartes-08 in Autoantibody Myositis |
RECRUITING | PHASE2 |
| NCT07089121 |
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders |
RECRUITING | PHASE1/PHASE2 |
| NCT06799247 |
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis |
RECRUITING | PHASE3 |
| NCT06304636 |
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma |
TERMINATED | PHASE1 |
| NCT06038474 |
Descartes-08 for Patients With Systemic Lupus Erythematosus |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05113342 |
Descartes-25 in Relapsed/Refractory Multiple Myeloma |
TERMINATED | PHASE1 |
| NCT04816526 |
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy |
TERMINATED | PHASE2 |
| NCT04524962 |
Study of Descartes-30 in Acute Respiratory Distress Syndrome |
TERMINATED | PHASE1 |
| NCT04436029 |
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy |
COMPLETED | PHASE2 |
| NCT04146051 |
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
ACTIVE_NOT_RECRUITING | PHASE2 |
